1213591-14-0

Basic information

• Product Name: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride
• CAS NO: 1213591-14-0
• Molecular Weight: 229.109
• Mol File: 1213591-14-0.mol
• Article Data: 27

Chemical Properties

• CAS DataBase Reference: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride(1213591-14-0)
• EPA Substance Registry System: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride(1213591-14-0)

Safety Data

• Hazardous Substances Data: 1213591-14-0(Hazardous Substances Data)

Usage

General Description

(S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride, also known as Clonidine, is a medication primarily used to treat high blood pressure and attention deficit hyperactivity disorder (ADHD). It works by stimulating alpha-2 adrenergic receptors in the brain, leading to a decrease in the sympathetic nervous system activity and a reduction in blood pressure. Clonidine is available in both oral and transdermal formulations and is sometimes used off-label to manage symptoms of opioid withdrawal, menopausal flushing, and anxiety. It may cause side effects such as drowsiness, dry mouth, and constipation, and it is important to consult a doctor before using this medication, as it has the potential for abuse and dependence.

Upstream product

• 934765-76-1 1,1-dimethylethyl (5-cyano-2,3-dihydro-1H-inden-2-yl)carbamate 
• 191014-55-8 2-methoxy-4-fluorobenzonitrile 
• 1228556-71-5 (S)-4-bromo-2,3-dihydro-1H-inden-1-amine 
• 1306763-31-4 tert-butyl N-[(1S)-4-cyano-2,3-dihydro-1H-inden-1-yl]carbamate 
• 60899-34-5 4-cyano-2,3-dihydro-1H-inden-1-one 
• 1306763-28-9 (R)-N-((R)-4-cyano-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide 
• 1306763-27-8 (R)-N-(4-cyano-2,3-dihydro-1H-indene-1-ylidene)-2-methylpropane-2-sulfinamide 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 1306763-24-5 (R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile 

Downstream Products

• 1027799-41-2 4-bromo-N-(5-cyano-2,3-dihydro-1H-inden-2-yl)-2-(trifluoromethyl)benzenesulfonamide 
• 1107650-45-2 (R)-3-amino-2,2-dimethyl-2,3-dihydro-1H-indene-5-carbonitrile 
• 1107650-46-3 (S)-3-amino-2,2-dimethyl-2,3-dihydro-1H-indene-5-carbonitrile 
• 1306763-30-3 (R)-tert-butyl 4-cyano-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1213203-23-6 (R)-(1-amino-2,3-dihydro-1H-indene-1-yl)-4-carbonitrile 
• 1307231-06-6 (R)-tert-butyl 4-(5-(3,4-diethoxybenzyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1306763-41-6 (R)-tert-butyl 2-(tert-butyldimethylsilyloxy)ethyl(4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate 
• 1306763-42-7 (R)-tert-butyl 2-(tert-butyldimethylsilyloxy)ethyl(4-(N-hydroxycarbamimidoyl)-2,3-dihydro-1H-inden-1-yl)carbamate 
• 1307231-07-7 (R)-tert-butyl 2-(tert-butyldimethylsilyloxy)ethyl(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate 
• 1307231-27-1 (R)-tert-butyl (2-((tert-butyldimethylsilyl)oxy)ethyl)(4-(N-((4-phenyl-5-(trifluoromethyl)thiophene-2-carbonyl)oxy)carbamimidoyl)-2,3-dihydro-1H-inden-1-yl)carbamate 
• 1306760-86-0 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile 

Relevant articles and documents

AMINO-PYRIMIDINE AMIDES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein, compositions including the compounds and methods of using the compounds.

AMINO-PYRIMIDINE CYCLO-AMIDES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and n are as defined herein, compositions including the compounds and methods of using the compounds.

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

We report here a short enantioselective synthesis of Ozanimod, a potent modulator of the enzyme Sphingosine-1-phosphate receptor (S1PR), recently approved by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. Amongst different synthetic approaches explored, we achieved the best result introducing the stereogenic centre in the last step through imine asymmetric transfer hydrogenation (ATH) using Wills’ catalysts. Besides the reduced numbers of enantiomeric purity controls required, this process culminates in an exceptionally high enantioselective reductive amination obtained with commercially available tethered Ru catalysts. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in 5 steps in 62 % overall yield and 99 % ee.